⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 2, 2024Expert Review of VaccinesOpen Access

Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

Rong Tang Ying Zeng Yu Zhou Qi Liang Wei Kang Zhonghua Yang Xiaoxiang Zheng Xia Zang Hongxing Pan Jing Jin Fengcai Zhu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Background Vaccination remains the cornerstone of defense against COVID-19 globally. This study aims to assess the safety and immunogenicity profile of innovative vaccines LYB001.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tang et al. (2024) studied this question.

synapsesocial.com/papers/68e6bbe0b6db64358763cd8f https://doi.org/10.1080/14760584.2024.2337051

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 studyEarly-Phase Clinical Trial · 2023 · 41 citations
2Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial2024 · 3 citations
3The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial2024 · 5 citations
4Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Original Research · 2026 · 4 citations
5Preclinical evaluation of a cross-protective ß-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF592024 · 2 citations

More related papers

Low dosage of a novel SARS-COV-2 mRNA-VLP vaccine elicits equivalent cell-mediated immunity to a licensed mRNA vaccine 22600432026
Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial2021
A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.2026

More from Expert Review of Vaccines

The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysisSat,
Virus-like particle vaccines: from antigen architecture to antigen presentation and adaptive immune responsesWed,